Abstract:The neuropathological criteria of anaplasia to distinguish between IDH-mutant astrocytomas of WHO grade 2 and 3 are ill-defined by the WHO 2021 classification. Following the positive phase III trial results and the expected approval of Vorasidenib for grade 2 astrocytomas, identifying prognostic markers distinguishing grade 2 and 3 tumors remains crucial. We retrospectively searched our institutional database for patients meeting the diagnostic criteria for IDH-mutant astrocytomas per the WHO 2021 classification. Clinical, neuropathological, and molecular data were collected, and outcomes compared using log-rank analysis. Centralized slide review is ongoing to exclude inter-rater variability due to the study's retrospective nature. We identified 99 patients with IDH-mutant astrocytomas in which detailed neuropathological and clinical information were available for review, including 63 tumors (63.6%) which were assigned to WHO grade 2 and 36 tumors (36.4%) assigned to WHO grade 3. At a median follow-up of 7.5 years, median progression-free survival was 5.7 years for WHO grade 2 tumors and 4.4 years for WHO grade 3 tumors. Median overall survival for WHO grade 2 and WHO grade 3 tumors was not reached. On univariate analysis, higher WHO grade, an increased number of mitoses, elevated Ki67 indices and the presence of contrast-enhancement on pre-operative imaging were associated with less favourable outcome. However, only the presence of contrast-enhancement retained its prognostic significance when forwarded into a multivariate model ( p = 0.034 for overall survival, p = 0.012 for progression-free survival). The findings on the association between contrast-enhancement and outcome were confirmed in treatment-based subgroups, including individuals treated with a watch-and-scan approach ( n = 30), radiotherapy ( n = 25), or chemotherapy ( n = 33). While our findings await confirmation in larger prospective cohorts, neuropathological criteria for anaplasia might need to be accompanied by clinical information including contrast enhancement to prognostically distinguish grade 2 from grade 3 tumors particularly in patients undergoing biopsy given the risk for undersampling.

Treatment outcome of IDH1/2 wildtype CNS WHO grade 4 glioma histologically diagnosed as WHO grade II or III astrocytomas

Isocitrate Dehydrogenase 1/2 Wildtype Adult Astrocytoma with WHO Grade 2/3 Histological Features: Molecular Re-Classification, Prognostic Factors, Clinical Outcomes

Improved prognostic stratification of patients with isocitrate dehydrogenase-mutant astrocytoma

Path-44. Clinical And Radiographic Predictors Of Prognosis In Astrocytoma, Idh-Mutant, Who Grade 4

Intentionality during hypnosis: an ironic process analysis.

Dissecting the prognostic signature of patients with astrocytoma isocitrate dehydrogenase-mutant grade 4: a large multicenter, retrospective study

Path-12. Clinical And Neuropathological Markers For Distinguishing Between Idh-Mutant Astrocytomas Of Who Grade 2 And 3

Anatomical and subcortical invasiveness in diffuse low-grade astrocytomas differ between IDH status and provide prognostic information

Novel insight into histological and molecular astrocytoma, IDH‐mutant, Grade 4 by the updated WHO classification of central nervous system tumors

Adult IDH Wild-Type Lower-Grade Gliomas Should Be Further Stratified

Path-16. Molecular Alterations In Idh-Mutant Astrocytoma: A Multi-Institutional Retrospective Study

IDH Mutant Lower Grade (WHO Grades II/III) Astrocytomas Can Be Stratified for Risk by CDKN2A, CDK4 and PDGFRA Copy Number Alterations.

Ncmp-11. Factors Influencing Management Strategy And Clinical Outcomes In Low-Grade Idh-Mutant Astrocytoma: A 10-Year Institutional Case Series

Molecular Correlates of Long Survival in IDH-Wildtype Glioblastoma Cohorts.

Health-Related Quality of Life and Treatment Satisfaction of Patients with Malignant IDH Wild-Type Gliomas and Their Caregivers

Prognostic value of DNA methylation subclassification, aneuploidy, and CDKN2A/B homozygous deletion in predicting clinical outcome of IDH mutant astrocytomas

Integrated Analysis of the Clinical and Molecular Characteristics of IDH Wild-Type Gliomas in the Chinese Glioma Genome Atlas

IDHwt glioblastomas can be stratified by their transcriptional response to standard treatment, with implications for targeted therapy

Exth-08. Ivosidenib Therapy For Idh-Mutant Who Grade 4 Astrocytoma

Cnsc-21. The Efficacy Of Tumor Treating Fields In Treating Idh-Mutant Astrocytoma, Who Grade 4: An Early Result From Shanghai Huashan Hospital

Clinical and radiographic characteristics of diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma: a single institution review